Thanks for posting, Christine. I am a little confused about the ending of the article, which reads:
"Interestingly, Perez also found that estrogen-receptor-positive tumors experienced a 15 percent improvement, even though many physicians had believed these tumors did not respond well to Herceptin.
'That's going to be news to a lot of people,' Perez said."
I wasn't aware that there was a question about the efficacy of Herceptin in Her2+/ER+ patients, and don't know what the "15% improvement" refers to.
Does anyone know?
Hopeful
|